Corner Therapeutics files Form D for $48.3 million equity offering tied to AI3 Bio merger
The filing shows the offering followed a merger transaction and lists eight investors who have already put in money, with the full amount sold.
SEC filing (2)
Latest
7 stories
Wednesday, November 4
Tuesday, October 27
Conexeu Sciences discloses private placement, special warrants and share issuances in 8-K
Filing covers a $3.00-per-Unit raise, Canadian special warrants, consultant stock grants, and warrant exercises from mid-September through mid-October 2026.
SEC filing (3)
Friday, October 23
OS Therapies closes first tranche of warrant inducement offer for $7.2 million
Seven warrant holders exercised shares on October 15, 2026, giving OS Therapies cash it says will help fund Herlystic regulatory filings due in the fourth quarter.
SEC filing (2)
Wednesday, October 21
Arcus files preliminary prospectus supplement, cites new casdatifan ccRCC data
Arcus proposed a common stock offering through underwriters Jefferies, Leerink Partners and TD Cowen, pointing to casdatifan results and an estimated $694.0 million cash balance.
SEC filing (3)
Thursday, October 15
Recursion prices $200M offering, reports Sanofi milestone and TUPELO, DAHLIA data
The company priced a 61.5 million share offering at $3.25 as Sanofi exercised an option on a first collaboration candidate and new REC-4881 and REC-1245 trial data emerged.
SEC filing (4)
Tuesday, October 13
Alaunos acquires Velaris Therapeutics, lines up $350 million PIPE financing
The October 13, 2026 merger and private placement bring pulmonary hypertension programs to Alaunos alongside a Fairmount-led investor group.
SEC filing (2)
Monday, October 5
Spyre Therapeutics files preliminary prospectus for common stock offering
The clinical-stage immunology company priced an undisclosed share count as of October 5, 2026, with stock last trading at $93.19.
SEC filing (3)